Michael McClung
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1477580207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $810,516 of the $1,300,684 with a category attached, or 62.3%. Amgen accounts for 95.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $360,528 and has fallen 59.0% since, to $147,799 in 2025. Among endocrinology, diabetes & metabolism clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,414 payments — averaging $919.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.2M
- AstraZeneca$21K
- Kyowa Kirin, Inc.$9K
- UCB SA$8K
- Novo Nordisk$6K
- Pfizer$5K
- plus $11K from 10 others
Across 25 payments — averaging $2163.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$42K
- E.r. Squibb & Sons, L.L.C.$10K
- Radius Health, Inc.$2K
What the payments were for
- Consulting fees$318,28624%
- Speaking & faculty fees$810,51662%
- Travel & lodging$147,97111%
- Food & beverage$23,9112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1,326 | $1,240,763 |
| AstraZeneca | 31 | $21,051 |
| Kyowa Kirin, Inc. | 16 | $9,237 |
| UCB SA | 5 | $8,008 |
| Novo Nordisk | 2 | $6,000 |
| Pfizer | 3 | $4,621 |
| Radius Health, Inc. | 11 | $3,962 |
| AbbVie | 7 | $2,724 |
| Sumitomo Pharma America, Inc. | 2 | $2,085 |
| Myovant Sciences Inc. | 2 | $646 |
| Celltrion, Inc. | 1 | $500 |
| Astellas Pharma US Inc | 3 | $377 |
| Organon | 1 | $332 |
| Ascendis Pharma Endocrinology Inc | 2 | $152 |
| Bayer | 1 | $114 |
| Therapeuticsmd, Inc. | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,300,684 in reported general payments places this provider in the 95th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Other endocrinology, diabetes & metabolism in Portland
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Andrew AhmannPortland$56K
- Matthew RiddlePortland$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.